Athira Pharma, Inc. (NASDAQ:ATHA) Sees Large Decrease in Short Interest

Athira Pharma, Inc. (NASDAQ:ATHA) was the target of a significant decline in short interest in December. As of December 31st, there was short interest totalling 1,170,000 shares, a decline of 17.6% from the December 15th total of 1,420,000 shares. Approximately 3.3% of the company’s shares are sold short. Based on an average trading volume of 4,600,000 shares, the short-interest ratio is presently 0.3 days.

Analyst Upgrades and Downgrades

Separately, Mizuho lowered shares of Athira Pharma from an “outperform” rating to a “neutral” rating and decreased their price objective for the stock from $5.00 to $0.50 in a report on Thursday, September 19th.

Athira Pharma Stock Down 2.2 %

Shares of NASDAQ:ATHA traded down $0.01 during trading on Thursday, hitting $0.53. The stock had a trading volume of 32,119 shares, compared to its average volume of 175,180. The company has a market capitalization of $20.50 million, a PE ratio of -0.19 and a beta of 2.99. The firm’s fifty day moving average is $0.61 and its 200 day moving average is $1.39. Athira Pharma has a 12 month low of $0.41 and a 12 month high of $4.30.

Athira Pharma (NASDAQ:ATHA) last announced its earnings results on Thursday, November 7th. The company reported ($0.75) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.05. Equities research analysts expect that Athira Pharma will post -2.35 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. American Century Companies Inc. grew its stake in shares of Athira Pharma by 9.4% in the second quarter. American Century Companies Inc. now owns 38,940 shares of the company’s stock worth $103,000 after acquiring an additional 3,333 shares during the last quarter. Renaissance Technologies LLC increased its stake in Athira Pharma by 3.5% during the 2nd quarter. Renaissance Technologies LLC now owns 271,488 shares of the company’s stock valued at $719,000 after purchasing an additional 9,164 shares in the last quarter. XTX Topco Ltd bought a new stake in Athira Pharma during the 2nd quarter valued at about $60,000. Forefront Analytics LLC raised its holdings in Athira Pharma by 126.0% in the second quarter. Forefront Analytics LLC now owns 46,595 shares of the company’s stock worth $123,000 after buying an additional 25,979 shares during the last quarter. Finally, Invst LLC bought a new position in shares of Athira Pharma in the second quarter worth approximately $68,000. Hedge funds and other institutional investors own 57.12% of the company’s stock.

Athira Pharma Company Profile

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.